Radioactive therapy shows promise for kids with neuroblastoma
NCT ID NCT03966651
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a radioactive drug called 177Lu-DOTATATE in one child with neuroblastoma that had come back or not responded to standard treatments. The drug targets tumor cells that have a specific marker (somatostatin receptors). The goal was to find a safe dose. The study is complete, but results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-DOTATATE (a radioactive drug that targets tumor cells)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat neuroblastoma.
What could go wrong
This is a very early phase 1 trial with only 1 participant, so safety and effectiveness are not yet known. The treatment involves radiation, which carries risks like damage to healthy organs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Angers
Angers, France
-
CHU Besançon
Besançon, France
-
CHU Dijon
Dijon, France
-
CHU Nancy
Nancy, France
-
CHU Nantes
Nantes, France
-
CHU Pellegrin
Bordeaux, France
-
CHU Reims
Reims, France
-
CHU Strasbourg
Strasbourg, France
-
CHU de Grenoble
Grenoble, France
-
CHU de Toulouse - Hôpital des enfants
Toulouse, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar Lambret
Lille, France
-
Hopital Arnaud de Villeneuve
Montpellier, France
-
IUCT-O
Toulouse, France